Health officials in the Democratic Republic of the Congo have recorded more than 10,400 cases since May in what has become the country's fastest-growing Ebola outbreak. The newly authorized trials, which include a candidate developed by the University of Oxford, the Serum Institute of India, and Moderna, directly address the Bundibugyo strain rather than the previously targeted Zaire strain. Public health teams expect clinical results by early 2027 while cross-border monitoring accelerates to manage cases emerging in neighboring countries. Meanwhile, international responders are reinforcing basic containment measures and opposing travel restrictions to maintain effective outbreak interventi…
Key points
Clinical trial results for the two newly authorized Bundibugyo Ebola vaccines are not exp…: Clinical trial results for the two newly authorized Bundibugyo Ebola vaccines are not expected until early 2027.
Health officials emphasize that vaccines must be paired with core measures including isol…: Health officials emphasize that vaccines must be paired with core measures including isolation, contact tracing, and safe burials.
The World Health Organization is urging nations to avoid travel bans that impede transpar…: The World Health Organization is urging nations to avoid travel bans that impede transparent reporting and damage outbreak containment.
Sources checked by our analysis pipeline: 1
Vaccines were designed for the Bundibugyo virus that has killed more than 5,300 in the DR Congo.
Incredible celebrations as last patient leaves a DRC Ebola centre
The World Health Organization (WHO) has approved clinical trials for two new Ebola vaccines, as doctors fight to control the largest outbreak in the history of the Democratic Republic of the Congo (DRC).
On Monday, WHO expert groups recommended adding two vaccine trials designed to fight the Bundibugyo strain, which has killed more than 5,300 people, most in the DRC, since May.
Recommended Stories
list of 3 items- list 1 of 3Attackers kill nurse, injure health worker responding to DRC Ebola case
- list 2 of 3Ebola cases in DR Congo surpass 10,000 in fastest-growing outbreak
- list 3 of 3Incredible celebrations as last patient leaves a DRC Ebola centre
Public health agencies have struggled to contain the Bundibugyo virus, which has a fatality rate of 50 percent due to the lack of a vaccine or treatments designed specifically for the strain.
WHO chief Tedros Adhanom Ghebreyesus said a trial that began last…
Medical developments for the Detroit defensive leader offer immense relief following a frightening fourth-quarter scene that halted Sunday's matchup at Ford Field. The former first-round pick has begun regaining upper-body mobility while retaining complete function in his lower extremities. His ongoing hospital recovery marks a critical turnaround for both the franchise captain and the team's defensive core.
The humanitarian volunteer's repatriation activates established national protocols to receive the patient into a specialized high-consequence infectious disease unit. Officials maintain that the domestic threat is minimal despite the infection stemming from the deadliest outbreak in DR Congo's history. The crisis has reached unprecedented geographic scale, complicated by a complete lack of approved treatments for this specific strain.
Surging availability and elevated purity levels have dramatically reshaped the United Kingdom's substance abuse landscape, creating new pressures for public health services. While nationwide drug mortality rates recorded their first annual dip in over a decade, severe regional divides persist across formerly industrial communities. These evolving consumption habits are also being compounded by the rapid spread of lower-cost party drugs and highly potent synthetic substances.